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Impact of histological response 
after neoadjuvant therapy 
on podocalyxin as a prognostic 
marker in pancreatic cancer
Annika Eurola1, Ari Ristimäki2,3, Harri Mustonen1, Anna‑Maria Nurmi1, Jaana Hagström2,4, 
Caj Haglund1,5 & Hanna Seppänen 1,5*
Podocalyxin overexpression associates with poor survival in pancreatic cancer (PDAC). We 
investigated whether podocalyxin expression correlates with treatment response or survival in 
neoadjuvant‑treated PDAC. Through immunohistochemistry, we evaluated podocalyxin expression 
in 88 neoadjuvant and 143 upfront surgery patients using two antibodies. We developed a six‑tier 
grading scheme for neoadjuvant responses evaluating the remaining tumor cells in surgical specimens. 
Strong podocalyxin immunopositivity associated with poor survival in the patients responding poorly 
to the neoadjuvant treatment (HR 4.16, 95% CI 1.56–11.01, p = 0.004), although neoadjuvant patients 
exhibited generally low podocalyxin expression (p = 0.017). Strong podocalyxin expression associated 
with perineural invasion (p = 0.003) and lack of radiation (p = 0.036). Two patients exhibited a complete 
neoadjuvant response, while a strong neoadjuvant response (≤ 5% of residual tumor cells) significantly 
associated with lower stage, pT‑class and grade, less spread to the regional lymph nodes, less 
perineural invasion, and podocalyxin negativity (p < 0.05, respectively). A strong response predicted 
better survival (HR 0.28, 95% CI 0.09–0.94, p = 0.039). In conclusion, strong podocalyxin expression 
associates with poor survival among poorly responding neoadjuvant patients. A good response 
associates with podocalyxin negativity. A strong response associates with better outcome.
Pancreatic cancer has now become the third most common cause of cancer-related death. In recent decades, the 
incidence of pancreatic cancer has increased, and survival rates remain poor and largely unchanged, with an 
overall five-year survival rate of 6% to 10%1. Under the most optimal situation, with localized, resectable disease, 
five-year survival can reach up to 37%2–4.
Many studies have shown that neoadjuvant therapy (NAT) is safe and effective for locally advanced and 
borderline-resectable  disease5–9. Assessing the histological NAT effect in a post-pancreatectomy pancreatic ductal 
adenocarcinoma (PDAC) specimen is challenging, since some histological features of the treatment response, 
such as necrosis, fibrosis, and tumor cell atypia, overlap with features seen in untreated  PDAC10. Furthermore, 
few schemes for evaluating the histopathological grading of the residual, viable tumor cells in the post-pan-
createctomy specimen have emerged. Such schemes rely on the percentage of visible, severely degenerative, or 
viable residual cancer cells in the  specimen11–14. Among these schemes, the Evans and the College of Ameri-
can Pathologists (CAP) grading systems appear to correlate with overall and disease-free survival (DFS)15–17. 
These systems have been criticized, however, for their lack of precision, clarity, simplicity, and clinical  utility18. 
Recently, the Amsterdam International Consensus Meeting provided an overview listing statements regarding 
neoadjuvant response scoring in pancreatic cancer. Among other statements, response should specifically assess 
residual, rather than regressive, tumor cells and the defining criteria describing the residual tumor cells should 
be objective and repeatable rather than  subjective19.
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A sialomucin, podocalyxin is a transmembrane protein closely related to hematopoietic stem cell marker 
 CD3420. It was first identified in the glomeruli, where it maintains the structure of podocytes and filtration slits 
through charge repulsion resulting from its negative  charge21–23. Podocalyxin also appears in other normal tis-
sues like the vascular  endothelia24 and hematopoietic stem  cells25. Podocalyxin expression has been reported 
in numerous malignancies including  PDAC26–31, colorectal  carcinoma32–35, hepatocellular  carcinoma36,37, and 
gastric and esophageal  cancers38,39. A high podocalyxin expression, in particular, associates with poor clinical 
outcomes in multiple cancers including colorectal  cancer32,33,35,  PDAC28, and gastric and esophageal  cancers38–41.
The upregulation of podocalyxin appears necessary for the epithelial-mesenchymal transition, characterized 
by migratory and invasive behavior and involvement in metastatic events in  cancer41–43. Furthermore, this upreg-
ulation appears to promote cancer cell proliferation, prevent apoptosis, promote tumorigenesis, and participate 
in cancer-cell  renewal40,41,44. In addition, podocalyxin plays a role in prompting resistance to chemotherapeutic 
agents like  cisplatin45,46, one of the drugs used to treat  PDAC8. In PDAC, polyclonal (pAb) and monoclonal 
(mAb) antibodies were previously used to detect podocalyxin, and poor disease-specific survival (DSS) has been 
associated with both strong pAb and mAb staining as well as combined strong pAb–mAb  staining28.
The role and underlying mechanisms of podocalyxin in neoadjuvant-treated cancer remain poorly under-
stood. Podocalyxin is an independent factor predicting a poor prognosis in  PDAC28, but has not been exam-
ined as an independent factor of prognosis in neoadjuvant-treated PDAC patients. The association between 
podocalyxin expression and earlier disease progression in PDAC remains unstudied, and whether podocalyxin 
works as a response marker following NAT is unknown. This study, therefore, aimed to clarify the relationship 
between podocalyxin and NAT in strong and poor NAT responders and the relationship between podocalyxin 
and disease progression in PDAC.
Methods
We identified patients surgically treated for PDAC at Helsinki University Hospital between 2000 and 2016, 
finding 90 patients who received NAT and 144 propensity scored patients matched for age, sex, and time of 
surgery who underwent upfront surgery (US). Survival data and cause of death were collected from patient 
records, Statistics Finland, and the Finnish Population Registry. Patients who died of immediate postoperative 
complications were excluded (n=3).
Tumor tissue microarray and immunohistochemistry. Formalin-fixed and paraffin-embedded post-
pancreatectomy specimens were collected from hematoxylin-eosin stained samples and re-evaluated by expe-
rienced pathologists to confirm diagnosis and determine well-represented areas of PDAC for the tumor tissue 
microarray (TMA) preparation. Six 1.0-mm cores were drilled from each tumor with a semiautomatic tissue 
microarrayer (TMA Grand Master, TMA Control 3.0, 3D Histech, Hungary).
To identify and stain podocalyxin, two different antibodies that recognize two different amino acid residues 
were used. The monoclonal antibody (mAb) recognizes amino acid residues 189–192 of podocalyxin. It was 
created through the immunization of mice using undifferentiated human embryonic stem cells (hES), stem cell 
line SA167 (Cellartis, Gothenburg, Sweden, www. celle ctis- biore search. com), and establishing mAb production 
against hES by conventional hybridoma technology. This process has been previously described in  detail35. The 
polyclonal antibody (pAb) (HPA 2110, Atlas Antibodies, Stockholm, Sweden) recognizes amino acid residues 
278–415. Both mAb and pAb have been  validated47,48 and used in PDAC and podocalyxin studies  before26,28,35.
TMA blocks were cut into 4-µm sections, deparaffinized in xylene and rehydrated through a gradually 
decreasing concentration of ethanol to distilled water. Slides were treated in a PreTreatment module (Lab Vision 
Corp., Fremont, and Ca, USA) in Tris-Hcl (pH 8.5) buffer for 20 min at 98°C for antigen retrieval. Slides were 
immunostained with pAb and mAb in an Autostainer 480 (Lab Vision Corp., Fremont, CA, USA) by the Dako 
REAL EnVision Detection system, Peroxidase/DAB+, rabbit/mouse (Dako, Glostrup, Denmark). Tissues were 
incubated with the mAb (1:500 = 2.4 mg/ml) and with the pAb (1:250 = 0.1 mg/ml) at room temperature for one 
hour. A sample of podocalyxin-positive colon cancer tissue served as the positive control.
All TMA samples were evaluated by two independent, blinded investigators (AE and JH). The cytoplasmic 
staining intensity, in the PDAC cells, of podocalyxin stained with mAb and pAb was scored from 0 to 3: 0, nega-
tive; 1, weakly positive; 2, moderately positive; and 3, strongly positive (Fig. 1). The highest score across all six 
TMA samples was considered representative. In the case of differing scores, consensus was reached through 
re-evaluation.
Grading the response to neoadjuvant therapy. All well-represented, diagnostic post-pancreatectomy 
samples from 88 NAT patients were collected. We designed a six-tier scheme to grade the response to NAT by 
evaluating the percentage of remaining, viable tumor cells: 0, no viable, residual tumor cells (RTCs) (0%); 1, 
only some found with large magnification of 200–400× (≤5% RTCs); 2, easily found with large magnification 
of 200–400× (6–10% RTCs); 3, easily found with small magnification of 20–40× (11–50% RTCs); 4, only little 
effect identified (51–90% RTCs); and 5, no effect identified (91–100% RTCs). Samples were evaluated by an 
experienced pathologist AR together with AE.
Statistical analysis. For analytical purposes, a strong response to NAT was defined as a class 0 or 1 
response, corresponding to ≤5% RTCs. In the survival analysis, non-responders were defined as a class 4 or 
5 response corresponding to >50% RTCs, and responders as a class 0 to 3 response, ≤50% RTCs. Podocalyxin 
staining scores were combined and grouped as follows: 1, strong staining for both pAb and mAb (both scored 3); 
2, either exhibiting strong staining (either scored 3); and 3, both staining weakly (both scored 0–2), correspond-
ing to strong, moderate, and weak, respectively.
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To compare categorical variables, we used the Fisher’s exact and linear-by-linear tests and relied on 
the Mann–Whitney U test for continuous variables. For the survival analysis, we used the Cox regression, 
Kaplan–Meier, and the Aalen–Johansen models. The log-rank and Gray’s tests were used to test for statistical 
significance. In the progression-free survival (PFS) analysis, progression was defined as the recurrence of cancer, 
deaths related to pancreatic cancer, and other deaths were used as competing events. We considered p < 0.05 as 
statistically significant. All statistical analyses were calculated using SPSS (version 25, IBM Corp., Armonk, TX, 
USA) and STATA/MP (version 16.1, StataCorp LLC, College Station, Texas, USA).
This study complies with the Declaration of Helsinki and was approved by the Surgical Ethics Committee 
of the Helsinki University Hospital (Dnro HUS 226/E6/06, extension TMK02 §66 17 April 2013). The National 
Supervisory Authority of Health and Welfare also granted permission (Valvira Dnro 10041/06.01.03.01/2012).
Ethics approval. This study complies with the Declaration of Helsinki and was approved by the Surgical Eth-
ics Committee of the Helsinki University Hospital (Dnro HUS 226/E6/06, extension TMK02 §66 17 April 2013). 
The National Supervisory Authority of Health and Welfare granted permission to use the tissue samples without 
requiring individual informed consent in this retrospective study (Valvira Dnro 10041/06.01.03.01/2012).
Results
Response to neoadjuvant therapy. Among 88 NAT patients, gemcitabine-cisplatin was the most used 
NAT (n = 43, 48.9%), either with (n = 26, 30%) or without radiation therapy. All NATs used are described in 
Supplementary Table 1.
Among NAT patients, 2 (2.3%) had no viable residual tumor cells remaining and, thus, a complete response 
to NAT. A class 5 response with more than 90% of the RTCs remaining was identified in 39 (44.3%) patients, 
making it the most common response class. The distribution of all responses appears in Fig. 2.
A strong response to NAT was associated with neoadjuvant radiation (p = 0.046), lower stage (p = 0.015), 
lower pT-class (p = 0.005), less spread to the regional lymph nodes (p = 0.046), lower grade (p = 0.021), less 
perineural invasion (p = 0.009), and negative podocalyxin staining with both mAb (p = 0.023) and pAb (p = 
0.008). Sex, age, vascular resection, and resection margin or perivascular invasion did not correlate with a strong 
response to NAT (Table 1).
Podocalyxin expression. NAT patients exhibited a weaker (p = 0.049) and less strong podocalyxin immu-
noexpression compared to US patients using mAb (p = 0.017). In the combined mAb and pAb podocalyxin 
expression category we identified a statistical difference between the two groups so that the NAT patients had 
weak podocalyxin immunoexpression (p = 0.032) and US patients had moderate podocalyxin immunoexpres-
sion (p = 0.005). Using pAb staining, we detected no significant difference between the groups. Table 2 summa-
rizes the podocalyxin expression distribution.
In the NAT group, weaker podocalyxin immunoexpression using pAb was associated with R0 resection mar-
gin (p = 0.023), lower grade (p = 0.034), and less perineural invasion (p = 0.003). We also detected an association 
between NAT radiation therapy and weaker podocalyxin immunoexpression (p = 0.036) using mAb. We found 
no association between sex, age, vascular resection, stage, T-class, lymph node ratio (N), and perivascular inva-
sion and either staining method (Table 3).
Figure 1.  Immunohistochemical staining pattern of podocalyxin in neoadjuvant treated pancreatic ductal 
adenocarcinoma. Staining pattern of podocalyxin in neoadjuvant treated pancreatic ductal adenocarcinoma 
using monoclonal antibody, HES9 (1A-1D) and polyclonal antibody, HPA2110 (2A-2D). Representative 
images of podocalyxin expressions using HES9: (1A) negative expression with positivity in blood vessels, (1B) 
weak cytoplasmic positivity, (1C) moderate cytoplasmic positivity, and (1D) strong cytoplasmic positivity. 
Representative images of podocalyxin expression using HPA2110: (2A) negative expression with positivity 
in blood vessels, (2B) weak cytoplasmic positivity, (2C) moderate cytoplasmic positivity, and (2D) strong 
cytoplasmic positivity. Magnification is x200.
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Podocalyxin and survival. Strong podocalyxin immunopositivity did not correlate with DSS or PFS in the 
entire NAT group in a univariate analysis (hazard ratio [HR] 1.45, 95% confidence interval [CI] 0.56–3.56, p = 
0.466 and HR 1.19, 95% CI 0.38–3.78, p = 0.763). However, among non-responders (n = 59) (with >50% RTCs), 
strong podocalyxin immunopositivity associated with a poor DSS (HR 4.16, 95% CI 1.56–11.01, p = 0.004) 
compared to weak and moderate immunopositivity (see Fig. 3a). In addition, in the PFS univariate analysis, a 
strong podocalyxin immunopositivity associated with a poor outcome among non-responders (HR 3.20, 95% 
CI 1.02–10.07, p = 0.047), although we detected no difference between moderate and weak immunopositivity (p 
= 0.632; see Fig. 3b). Among responders (n = 29) (≤50% RTCs), podocalyxin did not associate with DSS or PFS.
In the DSS multivariate analysis among non-responders, a strong podocalyxin expression (HR 6.175, 95% 
CI 2.057–18.544, p = 0.001) associated with a poor survival. Other variables including age, stage, tumor size, 
adjuvant therapy, or perivascular invasion did not associate with DSS (Supplementary Table 2). In the PFS 
multivariate analysis of non-responders, a strong podocalyxin expression associated with a poor survival (HR 
4.06, 95% CI 1.33–12.37 p = 0.014; Supplementary Table 3). We could not carry out a DSS or PFS multivariate 
analysis among responders given the small number of patients.
Among the US group, a strong podocalyxin immunopositivity using pAb (HR 2.31, 95% CI 1.21–4.38, p = 
0.011; Fig. 3c) and mAb (HR 1.57, 95% CI 1.03–2.39, p = 0.035; Fig. 3d) associated with a poor outcome in the 
PFS survival analysis. In a multivariate PFS analysis, a strong podocalyxin expression (HR 7.13, 9% CI 3.30–15.44, 
p < 0.001), stage III (HR 1.59, 95% CI 1.01–2.51, p = 0.045), adjuvant therapy (HR 0.57, 95% CI 0.38–0.84, p = 
0.005), and perivascular invasion (HR 3.10, 95% CI 2.02–4.77, p < 0.001) associated with a poor survival (Sup-
plementary Table 4). In addition, strong podocalyxin positivity using pAb (HR 2.00, 95% CI 1.11–3.62, p = 0.022) 
and mAb (HR 1.77, 95% CI 1.18–2.64, p = 0.006) associated with a poor DSS. In the multivariate DSS analysis, a 
strong podocalyxin expression (p < 0.001), moderate podocalyxin expression (p = 0.001), perivascular invasion 
(p < 0.001), and adjuvant therapy (p < 0.001) associated with DSS (Supplementary Table 5).
Response to NAT and survival. A strong response to NAT (≤5% RTCs) associated with a better outcome 
in the DSS analysis (HR 0.28, 95% CI 0.09–0.94, p = 0.039; Fig. 4a). We failed to detect a significant difference 
in survival between the response group with ≤10% RTCs compared to the group with >10% RTCs (HR 0.52, 
95% 0.254–1.07, p = 0.074). Furthermore, we identified no difference between the groups with ≤50% and >50% 
RTCs (HR 1.52, 95% CI 0.86–2.70, p = 0.146) or between the groups with ≤90% and >90% RTCs (HR 1.45, 95% 
CI 0.87–2.40, p = 0.150).
A strong response to NAT (≤5% RTCs) associated with a better outcome in the PFS survival analysis (HR 
0.18, 95% CI 0.04–0.78, p = 0.022; Fig. 4b). Interestingly, we detected a difference between the groups with ≤10% 
and >10% RTCs in the PFS analysis (HR 0.39, 95% 0.18–0.84, p = 0.016), but not between the groups with ≤50% 
and >50% RTCs (HR 1.57, 95% CI 0.90–2.75, p = 0.112) or between the groups with ≤90% and >90% of RTCs 
(HR 1.61, 95% CI 0.997 2.60, p = 0.051).
Discussion
We demonstrate that podocalyxin overexpression in PDAC serves as an independent prognostic marker for poor 
prognosis in patients treated with NAT only if no significant response to NAT was recorded, whereby more than 
50% of the viable residual tumor cells appeared in the post-pancreatectomy specimen. When the response to 
NAT was moderate to complete, with 50% or less viable residual tumor cells, no association between podocalyxin 
expression and DSS was found. In addition, podocalyxin expression associated with poor clinicopathological 
factors in the NAT group. In general, NAT patients exhibited a weaker podocalyxin expression compared to US 
patients using mAb. We also demonstrated that podocalyxin overexpression serves as an independent prognostic 
factor for poor progression-free survival among NAT patients only if the response to NAT was insubstantial, 
such that more than 50% of the viable residual tumor cells could be seen post-pancreatectomy.
Total=88
1 (  5% residual tumor cells)
2 (6 - 10% residual tumor cells)
3 (11 - 50% residual tumor cells)
4 (51 - 90% residual tumor cells)
5 (> 90% residual tumor cells)








Figure 2.  Frequencies of the different neoadjuvant responses and the percentage of viable residual tumor cells.
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Table 1.  Neoadjuvant response associated with characteristics comparing strong responders (≤ 5% residual 
tumor cells) and poor responders (> 5% residual tumor cells). P-values representing the level of statistical 
significance are bolded. *Stage IV patients were excluded from the study. **Two patients experienced a 
complete response to NAT, one of whom had dysplastic changes and the tumor size was determined. ***Two 
patients lacked grade and resection margin information and two patients experienced a complete response, 
such that the grade could not be determined. Linear-by-linear and Chi square -tests were used for this table.
n (%) Strong response Poor response p value
8 (9.1) 80 (90.9)
Sex
Female 4 (50.0) 45 (56.3)
Male 4 (50.0) 35 (43.8) 1.000
Age
 < 65 5 (62.5) 37 (46.3)
 ≥ 65 3 (37.5) 43 (53.8) 0.471
Vascular resection
Yes 4 (50.0) 46 (57.7)
No 4 (50.0) 34 (42.5) 0.722
Radiation therapy
Yes 5 (62.5) 21 (26.3)
No 3 (37.5) 59 (73.8) 0.046
Stage
IA 3 (42.9) 7 (8.8)
IB 3 (42.9) 22 (27.5)
IIA 0 (0.0) 7 (8.8)
IIB 0 (0.0) 30 (37.5)




T1 3 (37.5) 17 (21.3)
T2 3 (37.5) 44 (55.0)
T3 0 (0.0) 17 (21.3)
T4 1 (12.5) 2 (2.5) 0.005
Missing** 1
N
N0 7 (87.5) 37 (46.3)
N1 1 (12.5) 31 (38.8)
N2 0 (0.0) 12 (15.0) 0.046
Grade
1 2 (25.0) 11 (13.8)
2 3 (37.5) 52 (65.0)
3 1 (12.5) 15 (18.8) 0.021
Missing*** 4
Resection margin
R0 2 (25.0) 18 (23.1)
R1 6 (75.0) 60 (76.9) 1.000
Missing***
Perineural invasion
Yes 2 (25.0) 59 (73.8)
No 6 (75.0) 21 (26.3) 0.009
Perivascular invasion
Yes 0 (0.0) 25 (31.3)
No 8 (100.0) 55 (68.8) 0.099
Negative pAb podocalyxin
Yes 5 (62.5) 13 (16.3)
No 3 (37.5) 67 (83.8) 0.008
Negative mAb podocalyxin
Yes 3 (37.5) 5 (6.3)
No 5 (62.5) 75 (93.8) 0.023
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Podocalyxin expression and its association with a poor survival in PDAC was described  previously26–31. For 
example, Saukkonen et al. (2015) showed that strong podocalyxin expression independently served as a prog-
nostic factor for a poor prognosis in PDAC in a study that used the same antibodies. However, patients receiving 
NAT were excluded and, to our knowledge, our study represents the first report describing the expression of 
podocalyxin in neoadjuvant-treated PDAC patients.
While podocalyxin serves as an independent marker of poor prognosis in treatment-naïve PDAC, the under-
lying mechanisms are not well understood. The upregulation of podocalyxin appears necessary for the epithe-
lial–mesenchymal transition, characterized by migratory and invasive behavior and the involvement metastatic 
events in  cancer41–43. Podocalyxin has been shown to promote cancer cell proliferation, prevent apoptosis, pro-
mote tumorigenesis and participate in cancer cell  renewal40,41,49,50. Some studies suggest that metastatic, circulat-
ing PDAC cells employ podocalyxin as a functional E- and L-selectin ligand promoting cell adhesion to vascular 
endothelia in  metastasis27,29. However, the causal relationship between a weaker podocalyxin expression and a 
better NAT response remains unclear. In PDAC, a preoperative tumor biopsy is difficult to obtain; thus, the pre-
operative podocalyxin expression is unknown. A comparative analysis of podocalyxin expression or the tumor 
cell density evaluation of the NAT response between the preoperative and postoperative tumor samples could 
be performed. Thus, we cannot draw a definitive conclusion regarding whether a weaker podocalyxin expression 
leads to a better NAT response or, alternatively, if a better NAT response leads to a weaker podocalyxin expres-
sion. Among poorly responding NAT patients, a strong podocalyxin expression associated with poor survival, 
similar to observations for treatment-naïve PDAC. Furthermore, in these patients, podocalyxin could be used 
as a survival marker. Among strong NAT responders, podocalyxin expression becomes generally weaker. Hence, 
podocalyxin can be used as a response marker, but is of no use as a survival marker in strong responders.
Furthermore, we show that podocalyxin serves as an independent prognostic factor of poor progression-
free survival in US patients. This supports findings from an earlier study of podocalyxin and DSS among US 
 patients28. Here, we detected a difference in survival, both DSS and PFS, between strong and weak podocalyxin 
expression, but not between moderate and weak podocalyxin expression, and these results agree with previous 
findings. Saukkonen et al. showed that strong podocalyxin expression compared to weak podocalyxin expression 
was associated with poor  survival28.
In addition, we found that only 2 (2.3%) patients exhibited a complete response to NAT. Chatterjee at al. 
described a similar complete response rate of 2.7%16 while White at al. described a complete response rate of 
6%14. We detected a significant association between the NAT response and survival between groups with 5% or 
fewer and groups with more than 5% residual tumor cells. We found no difference, however, in survival between 
groups with ≤10% and >10% RTCs, the groups with ≤50% and >50% RTCs, or the groups with ≤90% and >90% of 
RTCs. Thus, when using NAT, improvement in survival may only occur if the response to NAT is nearly complete, 
such that no more than 5% of residual tumor cells appear in the surgical specimen. A strong response to NAT 
was also associated with a better stage, T-class, lymph node ratio, grade, perineural invasion, and negative podo-
calyxin expression. Patients treated with NAT radiotherapy significantly more often exhibited a strong response 
to NAT, supporting its use as a part of NAT. In the study of Chatterjee et al. patients treated with neoadjuvant 
chemotherapy instead of chemoradiation had more residual tumor cells in the post-pancreatectomy  specimen16.
We designed a six-tier scheme to grade the response to NAT based on the percentage of viable residual tumor 
cells observed in the post-pancreatectomy specimen. This scheme mirrors previously established schemes. For 
example, Ishikawa et al. (1989) proposed a grading system with three categories based on the percentage of 
severely degenerative cancer cells: less than one-third, one-third to two-thirds, and more than two-thirds11. 
Evans et al. (1992) proposed a four-tiered system based on assessing the percentage of tumor cell destruction: I, 
destruction of <10% tumor cells; IIa, destruction of 10% to 50% of tumor cells; IIb, destruction of 51% to 90% of 
Table 2.  Podocalyxin staining intensities using polyclonal (pAb), monoclonal (mAb) and combined 
antibodies comparing the neoadjuvant (NAT) and upfront surgery (US) groups. Linear-by-linear test was used 
for this table.
n (%) NAT US p value
pAb
Strong 15 (17.0) 16 (11.2) 0.235
Moderate 30 (34.1) 63 (44.1) 0.167
Weak 25 (28.4) 44 (30.8) 0.768
Negative 18 (20.5) 20 (14.0) 0.206
mAb
Strong 13 (14.8) 41 (28.7) 0.017
Moderate 35 (39.8) 49 (34.3) 0.402
Weak 32 (36.4) 36 (25.2) 0.049
Negative 8 (9.1) 17 (11.9) 0.663
Combined
Strong 7 (8.0) 5 (3.5) 0.220
Moderate 14 (15.9) 47 (32.9) 0.005
Weak 67 (76.1) 91 (63.6) 0.032
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tumor cells; III, <10% viable tumor cells (>90% destroyed); and IV, no viable tumor  cells12. White et al. (2005) 
proposed a three-tier system similar to Evans based on the percentage of the remaining viable tumor cells: <10, 
10% to 90%, and >90%13. The College of American Pathologists (CAP) proposes using four categories: 0, no 
viable tumor cells; 1, single cells or small groups of cancer cells; 2, residual cancer outgrown by fibrosis; and 3, 
minimal or no tumor  kill14. The CAP and Evans grading schemes appear to correlate with overall and  DFS15,17.
Chatterjee et al. (2012) used the Evans and CAP grading systems, identifying a difference in survival between 
patients with only minimal residual tumor cells compared to patients with a moderate to poor  response16. They 
Table 3.  Association between patient characteristics and podocalyxin using the polyclonal (pAb) and the 
monoclonal antibody (mAb) in the neoadjuvant group.
n (%)
Podocalyxin, pAb Podocalyxin, mAb
Negative Weak Moderate Strong p value Negative Weak Moderate Strong p value
Sex
Female 8 (44.4) 10 (40.0) 23 (76.6) 8 (53.3) 4 (50.0) 17 (53.1) 15 (42.9) 5 (38.5)
Male 10 (55.6) 15 (60.0) 7 (23.3) 7 (46.7) 0.104 4 (50.0) 15 (46.9) 20 (57.1) 8 (61.5) 0.531
Age
 < 65 8 (44.4) 13 (52.0) 13 (43.3) 8 (53.3) 2 (25.0) 17 (53.1) 18 (51.4) 5 (38.5)
 ≥ 65 10 (55.6) 12 (48.0) 17 (56.7) 7 (46.7) 0.839 6 (75.0) 15 (46.9) 17 (48.6) 8 (61.5) 0.860
Vascular resection
Yes 11 (61.1) 10 (40.0) 19 (63.3) 10 (66.7) 4 (50.0) 16 (50.0) 22 (62.9) 8 (61.5)
No 7 (38.9) 15 (60.0) 11 (36.7) 5 (33.3) 0.376 4 (50.0) 16 (50.0) 13 (37.1) 5 (38.5) 0.326
Radiation therapy
Yes 5 (27.8) 8 (32.0) 9 (30.0) 4 (26.7) 5 (62.5) 10 (31.3) 9 (25.7) 2 (15.4)
No 13 (72.2) 17 (68.0) 21 (70.0) 11 (73.3) 0.924 3 (37.5) 22 (68.8) 26 (74.3) 11 (84.6) 0.036
Stage
IA 5 (27.8) 4 (16.7) 0 (0.0) 1 (6.7) 3 (42.9) 3 (9.4) 4 (11.4) 0 (0.0%)
IB 5 (27.8) 5 (20.8) 9 (30.0) 6 (40.0) 4 (57.1) 8 (25.0) 6 (17.1) 7 (53.8)
IIA 2 (11.1) 3 (12.5) 1 (3.3) 1 (6.7) 0 (0.0) 3 (9.4) 3 (8.6) 1 (7.7)
IIB 4 (22.2) 9 (37.5) 12 (40.0) 5 (33.3) 0 (0.0) 11 (34.4) 15 (42.9) 4 (30.8)




T1 5 (27.8) 8 (32.0) 5 (16.7) 2 (13.3) 3 (37.5) 8 (25.0) 8 (22.9) 1 (7.7)
T2 9 (50.0) 11 (44.0) 17 (56.7) 10 (66.7) 4 (50.0) 18 (56.3) 17 (48.6) 8 (61.5)
T3 4 (22.2) 4 (16.0) 6 (20.0) 3 (20.0) 0 (0.0) 5 (15.6) 8 (22.9) 4 (30.8)
T4 0 (0.0) 1 (4.0) 2 (6.7) 0 (0.0) 0.703 0 (0.0) 1 (3.1) 2 (5.7) 0 (0.0) 0.313
Missing** 1 1
N
N0 12 (66.7) 13 (52.0) 11 (36.7) 8 (53.3) 7 (87.5) 14 (43.8) 15 (42.9) 8 (61.5)
N1 4 (22.2) 10 (40.0) 13 (43.3) 5 (33.3) 1 (12.5) 12 (37.5) 15 (42.9) 4 (30.8)
N2 2 (11.1) 2 (8.0) 6 (20.0) 2 (13.3) 0.519 0 (0.0) 6 (18.8) 5 (14.3) 1 (7.7) 0.229
Grade
1 5 (27.8) 5 (20.0) 2 (6.7) 1 (6.7) 3 (37.5) 3 (9.4) 2 (15.4) 13 (14.8)
2 8 (44.4) 17 (68.0) 21 (70.0) 9 (60.0) 2 (25.0) 22 (68.8) 7 (53.8) 55 (62.5)
3 3 (16.7) 3 (12.0) 6 (20.0) 4 (26.7) 0.034 2 (25.0) 5 (15.6) 4 (30.8) 16 (18.2) 0.392
Missing*** 4 4
Resection margin
R0 18 (100.0) 19 (76.0) 19 (65.5) 10 (71.4) 7 (87.5) 24 (77.4) 27 (77.1) 8 (66.7)
R1 0 (0.0) 6 (24.0) 10 (34.5) 4 (28.6) 0.023 1 (12.5) 7 (22.6) 8 (22.9) 4 (33.3) 0.343
Missing**** 2 2
Perineural invasion
Yes 7 (38.9) 17 (68.0) 25 (83.3) 12 (80.0) 3 (37.5) 23 (71.9) 24 (68.6) 11 (84.6)
No 11 (61.1) 8 (32.0) 5 (16.7) 3 (20.0) 0.003 5 (62.5) 9 (28.1) 11 (31.4) 2 (15.4) 0.089
Perivascular invasion
Yes 3 (16.7) 6 (24.0) 13 (43.3) 3 (20.0) 0 (0.0) 7 (21.9) 15 (42.9) 3 (23.1)
No 15 (83.3) 19 (76.0) 17 (56.7) 12 (80.0) 0.339 8 (100.0) 25 (78.1) 20 (57.1) 10 (76.9) 0.099
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found no difference between Evans grade I, IIa, and IIb or CAP grades 2 and 3. Thus, a three-tier grading system 
has been proposed: no residual carcinoma, <5% residual carcinoma, and >5% residual  carcinoma16. By contrast, 
in the study by White et al. (2005), patients with a large residual tumor (class 5) experienced a shorter survival 
time than those with a moderate or good response to  NAT13.
In our progression-free survival analysis, we detected a difference between groups with 5% or less and more 
than 5% residual tumor cells, observing an additional difference between groups with 10% or less and more than 
10% residual tumor cells, but not between the other groups. Chatterjee et al. recommended using a three-tier 
grading system to group responses to complete, <5%, and >5% residual tumor cells. Our results regarding the 
progression-free survival identified a difference between groups with <10% and >10% residual tumor cells, sug-
gesting that perhaps additional groups are warranted.
Figure 3.  Kaplan–Meier and Aalen-Johansen survival by podocalyxin immunoexpression. (a) The association 
of disease-specific survival (DSS) and podocalyxin immunoexpression based on polyclonal (pAb), HPA2110 
and monoclonal antibodies (mAb), HES9 combined among non-responders. A categorization for podocalyxin 
expression with three groups was created as follows: 1, strong staining for both pAb and mAb (both scored 3); 2, 
either exhibiting strong staining (either scored 3); and 3, both staining weakly (both scored 0–2), corresponding 
to strong, moderate, and weak, respectively. Non-responders were defined as a class 4 or 5 response 
corresponding to > 50% residual tumor cells. Kaplan–Meier analysis. Log-rank test was used for statistical 
significance. (b) The association of progression-free survival (PFS) and podocalyxin immunoexpression based 
on polyclonal (pAb) and monoclonal antibodies (mAb) combined among non-responders. A categorization 
for podocalyxin expression with three groups was created as follows: 1, strong staining for both pAb and mAb 
(both scored 3); 2, either exhibiting strong staining (either scored 3); and 3, both staining weakly (both scored 
0–2), corresponding to strong, moderate, and weak, respectively. Non-responders were defined as a class 4 or 5 
response corresponding to > 50% residual tumor cells. Death from any cause (overall survival, OS) was used as 
a competing event. Aalen-Johansen analysis. Gray’s test was used for statistical significance. (c) The association 
of progression-free survival (PFS) and podocalyxin immunoexpression with polyclonal antibody HPA2110, 
(pAb) in the upfront surgery group. Podocalyxin expressions were grouped as follows: 1, strong staining for pAb 
(scored 3); and 2, moderate, weak or negative staining for pAb (scored 0–2) corresponding to strong and weak, 
respectively. Upfront surgery patients included for the analysis. Aalen-Johansen analysis. Death from any cause 
(overall survival, OS) was used as a competing event. Grays’ test was used for statistical significance. (d) The 
association of progression-free survival (PFS) and podocalyxin immunoexpression with monoclonal antibody 
HES9, (mAb) in the upfront surgery group. Podocalyxin expressions were grouped as follows: 1, strong staining 
for mAb (scored 3); and 2, moderate, weak or negative staining for mAb (scored 0–2) corresponding to strong 
and weak, respectively. Upfront surgery patients included for the analysis. Aalen-Johansen analysis. Death from 
any cause (overall survival, OS) was used as a competing event. Grays’ test was used for statistical significance.
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One strength to our study lies in its relatively large, well-described cohort of patients with histologically deter-
mined PDAC. We excluded other tumors of the pancreas or cancers originating from the bile ducts. The NAT 
and US groups were matched for age, sex, and time of surgery. Moreover, our data on the survival and follow-up 
are reliable and precise. To evaluate the neoadjuvant response, we designed the six-tier scheme adapting it from 
previously designed schemes. Our scheme follows the recommendations of the latest tumor response consen-
sus statements from the Amsterdam International Consensus  Meeting19. Furthermore, multiple representative 
samples for each patient were reviewed to evaluate the NAT response. Given these strengths, we acknowledge 
limitations to our study. The TMA samples are relatively small (1-mm diameter) and, thus, the representativeness 
of the cancer and podocalyxin staining may have suffered. Specifically, podocalyxin may be unevenly distributed 
in the tumor. These limitations were minimized by taking several (6) TMA samples per tumor and by scoring the 
podocalyxin intensity using the strongest intensity visible in the tumor. An experienced pathologist determined 
the TMA drilling spots on the specimen. Furthermore, the podocalyxin intensity scoring was determined by two 
independent investigators in order to minimize the effect of subjectivity. This study was conducted to clarify the 
relationship between podocalyxin staining and NAT, considering the response to NAT. Due to the retrospective 
nature of our study, implementation of NAT varies between patients. This study featured a limited number of 
patients with a good or strong response to NAT and, thus, we could not perform a multivariate survival analysis 
for those patients.
Conclusions
To our knowledge, this is the first report to show that podocalyxin serves as an independent predictor of a poor 
prognosis in neoadjuvant-treated PDAC patients, but only if the response to NAT is not significant. The causal 
relationship between a better NAT response, decreased podocalyxin expression, and an inability of podocalyxin to 
serve as a prognostic marker in NAT patients who respond well remains unclear. A complete or nearly complete 
response to NAT is rare, whereby those patients seem to benefit from NAT in terms of survival.
Data availability
Data supporting the results of this study is available upon request to the corresponding author.
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